Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Buy
74
LLY Quote, Financials, Valuation and Earnings
Last price:
$1,063.85
Seasonality move
:
2.33%
Day range:
$1,033.38 - $1,085.38
52-week range:
$623.78 - $1,111.99
Dividend yield:
0.58%
P/E ratio:
51.51x
P/S ratio:
15.98x
P/B ratio:
39.18x
Volume:
4.1M
Avg. volume:
3.2M
1-year change:
33.19%
Market cap:
$932.2B
Revenue:
$45B
EPS (TTM):
$20.22
Analysts' Opinion
-
Consensus RatingEli Lilly & Co. has received a consensus rating of Buy. The company's average rating is a Buy based on 18 Buy ratings, 7 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1,098.04, Eli Lilly & Co. has an estimated upside of 5.43% from its current price of $1,041.51.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $770.00 representing 26.07% downside risk from its current price of $1,041.51.
Fair Value
-
According to the consensus of 25 analysts, Eli Lilly & Co. has 5.43% upside to fair value with a price target of $1,098.04 per share.
LLY vs. S&P 500
-
Over the past 5 trading days, Eli Lilly & Co. has underperformed the S&P 500 by -4.15% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Eli Lilly & Co. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Eli Lilly & Co. has grown year-over-year revenues for 10 quarters straight. In the most recent quarter Eli Lilly & Co. reported revenues of $17.6B.
Earnings Growth
-
Eli Lilly & Co. has grown year-over-year earnings for 8 quarters straight. In the most recent quarter Eli Lilly & Co. reported earnings per share of $6.21.
Enterprise value:
964.8B
EV / Invested capital:
--
Price / LTM sales:
15.98x
EV / EBIT:
36.56x
EV / Revenue:
16.24x
PEG ratio (5yr expected):
0.43x
EV / Free cash flow:
149.90x
Price / Operating cash flow:
147.52x
Enterprise value / EBITDA:
34.11x
Gross Profit (TTM):
$49.3B
Return On Assets:
20.03%
Net Income Margin (TTM):
30.99%
Return On Equity:
106.26%
Return On Invested Capital:
33.81%
Operating Margin:
47.65%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $32.1B | $40.9B | $59.4B | $11.4B | $17.6B | |
| Gross Profit | $25.2B | $33.1B | $49.3B | $9.3B | $14.6B | |
| Operating Income | $9.4B | $14.4B | $26.4B | $4.4B | $8.4B | |
| EBITDA | $10.9B | $16.1B | $28.3B | $4.9B | $8.9B | |
| Diluted EPS | $5.42 | $9.14 | $20.22 | $1.07 | $6.21 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $17.8B | $17.6B | $23B | $31.4B | $62.1B | |
| Total Assets | $48.2B | $47.5B | $57.9B | $75.6B | $114.9B | |
| Current Liabilities | $13.7B | $15.7B | $22B | $24.7B | $40.1B | |
| Total Liabilities | $40.2B | $37.3B | $46.6B | $61.3B | $91.1B | |
| Total Equity | $8B | $10.2B | $11.3B | $14.3B | $23.9B | |
| Total Debt | $17.1B | $15.9B | $20.2B | $31.1B | $42.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $6.1B | $6B | $16.1B | $3.7B | $8.8B | |
| Cash From Investing | -$5.1B | -$10.3B | -$10.1B | -$4B | -$3B | |
| Cash From Financing | -$1.2B | $5B | $440.4M | $211.3M | $531M | |
| Free Cash Flow | -$164.9M | -$2.3B | $6.4B | -$458.9M | $6B | |
LLY
Sector
Market Cap
$932.2B
$28.1M
Price % of 52-Week High
93.66%
50.9%
Dividend Yield
0.58%
0%
Shareholder Yield
1.04%
-1.55%
1-Year Price Total Return
33.19%
-19.36%
Beta (5-Year)
0.348
0.498
Dividend yield:
0.58%
Annualized payout:
$5.20
Payout ratio:
24.15%
Growth streak:
10 years
Technicals
8-day SMA
Sell
Level
$1,072.68
200-day SMA
Buy
Level
$829.08
Bollinger Bands (100)
Buy
Level
742.98 - 1020.64
Chaikin Money Flow
Buy
Level
1.5B
20-day SMA
Sell
Level
$1,048.26
Relative Strength Index (RSI14)
Sell
Level
49.42
ADX Line
Sell
Level
28.13
Williams %R
Buy
Level
-83.98
50-day SMA
Buy
Level
$1,002.15
MACD (12, 26)
Buy
Level
18.81
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Neutral
Level
1.1B
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (8.0453)
Sell
CA Score
(Annual)
Level (-0.6336)
Sell
Beneish M-Score
(Annual)
Level (-2.1773)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-0.2314)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (9)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.
Stock Forecast FAQ
In the current month, LLY has received 18 Buy ratings 7 Hold ratings, and 0 Sell ratings. The LLY average analyst price target in the past 3 months is $1,098.04.
-
Where Will Eli Lilly & Co. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Eli Lilly & Co. share price will rise to $1,098.04 per share over the next 12 months.
-
What Do Analysts Say About Eli Lilly & Co.?
Analysts are divided on their view about Eli Lilly & Co. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Eli Lilly & Co. is a Sell and believe this share price will drop from its current level to $770.00.
-
What Is Eli Lilly & Co.'s Price Target?
The price target for Eli Lilly & Co. over the next 1-year time period is forecast to be $1,098.04 according to 25 Wall Street analysts, 18 of them rate the stock a Buy, 0 rate the stock a Sell, and 7 analysts rate the stock a Hold.
-
Is LLY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Eli Lilly & Co. is a Buy. 18 of 25 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of LLY?
You can purchase shares of Eli Lilly & Co. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Eli Lilly & Co. shares.
-
What Is The Eli Lilly & Co. Share Price Today?
Eli Lilly & Co. was last trading at $1,063.85 per share. This represents the most recent stock quote for Eli Lilly & Co.. Yesterday, Eli Lilly & Co. closed at $1,041.51 per share.
-
How To Buy Eli Lilly & Co. Stock Online?
In order to purchase Eli Lilly & Co. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get LLY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
LLY
Sector
P/E ratio
51.51x
24.09x
PEG ratio
0.43x
-0.01x
P/B ratio
39.18x
1.83x
Price / LTM sales
15.98x
1.59x
Growth Metrics
LLY
Sector
Revenue growth
53.87%
4.68%
Earnings growth
479.29%
10.88%
Revenue (5-year growth)
15.08%
6.45%
Earnings forecast
$7.17
-$0.18
Profitability
LLY
Sector
Profitability FY 2024
$36.6B
$3.6M
Return on invested capital
33.81%
-31.87%
Return on assets
20.03%
-28.18%
Return on equity
106.26%
-37.89%
Earnings Date
Last Earnings Date
Oct
30
Next Earnings Date
Feb
4
Estimated Next Earnings Date
Jan
29
Balance Sheet
LLY
Sector
Total cash
$9.9B
$26.2M
Short term investments
$154.8M
$25.7M
Total assets
$78.7B
$76.7M
Long term debt
$42.5B
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
